Innogenetics to continue development of HCV diagnostics
Ghent – Novartis and Innogenetics have settled a patent litigation suit, giving Innogenetics non-exclusive rights to continue to develop and commercialize HCV immunodiagnostics in undisclosed European countries. Chiron Corp., now part of Novartis, originally filed suit in the Ghent court. Chiron had been seeking up to a25 million in damages. It will now receive an undisclosed upfront payment and is eligible for milestones.